<DOC>
	<DOCNO>NCT01804777</DOCNO>
	<brief_summary>The purpose study determine administration amiloride , observe enhance natriuresis , reduction blood pressure weight compare administration hydrochlorothiazide Type 2 Diabetics .</brief_summary>
	<brief_title>Epithelial Sodium Channel ( ENaC ) Novel Mechanism Hypertension Volume Expansion Type 2 Diabetes</brief_title>
	<detailed_description>Renal sodium retention extracellular fluid volume expansion hallmark nephrotic syndrome . There abundant evidence occur even absence activation hormone know activate renal Na transporter . Proteinuria reflect glomerular damage , also function risk factor cardiovascular disease , stroke , end stage renal disease associate extracellular volume expansion high BP . In natural course Type II diabetes , microalbuminuria elevation blood pressure think occur around time . Blood pressure microalbuminuric diabetic sensitive dietary salt intake normoalbuminuric patient despite group similar aldosterone plasma renin activity level . Proteolytic processing ENaC subunit might provide primary defect renal sodium handle microalbuminuric individual . However , proteinuria consistently identify risk factor incipient elevation blood pressure study elevate blood pressure predict advent microalbuminuria . Analyses normotensive normoalbuminuric subject previous study find high urinary albumin level normal range predict incident hypertension . A similar finding see non-diabetic cohort . These study suggest disparate result may relate cut define microalbuminuria . Another possible explanation ENaC activator , like plasmin , contribute generation incident hypertension individual . Levels albuminuria may necessarily reflective ENaC activator level may vary individual individual . Perhaps urinary plasmin plasminogen provide robust biomarker individual may develop hypertension . Recent evidence suggest individual glomerular damage , protease normally find urine enter urinary space aberrantly cleave ENaC . In set , filter plasminogen ( inactive precursor ) convert plasmin ( active protease ) urokinase express tubular epithelial lumen . The proteolytic activation ENaC would generate primary defect renal sodium handling , mechanism may particularly important factor lead increase extracellular fluid volume BP accompany nephrotic syndrome . While previous study examine role amiloride low-renin hypertension , additional agent conventional treatment hypertension , human trial test whether ENaC inhibitor impact blood pressure volume status set proteinuria . Over ten year period , million diabetic , 5.3 % Type II diabetic 28 % Type I diabetics develop macroscopic proteinuria .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>1 . Age 18 80 yr randomization 2 . History Type 2 Diabetes 3 . Presence systolic hypertension prehypertension ( average systolic blood pressure ( SBP ) ≥120 mmHg &lt; 180 mmHg . ) 4 . Urinary protein/creatinine ratio &gt; 300 mg/g creatinine screen 5 . Hemoglobin A1C &lt; 8 % 6 . Willing able give inform consent 1 . Average SBP ≥180 mmHg diastolic blood pressure ( DBP ) ≥110 mmHg 2 . Current symptomatic heart failure , history New York Heart Association Class III IV congestive heart failure , leave ventricular ( LV ) ejection fraction ( method ) &lt; 25 % ; patient may harm withdrawal diuretic 3 . Serum potassium level &lt; 3.5 &gt; 5.0 screen 4 . History hyperkalemia last two year ( serum K &gt; 5.5 ) 5 . Contraindication use hydrochlorothiazide amiloride 6 . Unstable angina pectoris acute myocardial infarction ( MI ) last 3 month 7 . Known secondary cause hypertension ( HTN ) ( screen condition require ) 8 . Estimated glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m² , determine validated estimate equation 9 . On expect immunosuppressive therapy 10 . Any history solid organ transplantation 11 . Significant dementia 12 . Other factor likely limit adherence trial ( eg . alcohol substance abuse , plan move next year , history nonadherence medication , appointment medical care , reluctance close family member participate trial , lack support primary healthcare provider ) 13 . Participation another investigational trial within 4 week screen visit 14 . Arm Circumference large small allow accurate blood pressure measurement 15 . Pregnancy currently try become pregnant ( although unlikely age limit 16 . Incarceration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>ENaC</keyword>
	<keyword>Amiloride</keyword>
	<keyword>Hydrochlorothiazide ( HCTZ )</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Natriuresis</keyword>
	<keyword>Proteinuria</keyword>
</DOC>